{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:29:36Z","timestamp":1793744976549,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Xylazine has emerged as a consistent part of the unregulated drug supply in recent months. We discuss major domains of xylazine\u2019s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine\u2019s public health and policy context. As an interdisciplinary team from across the USA, we have pooled our knowledge to provide an overview of xylazine\u2019s current and emerging contexts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To inform this essay, the pertinent literature was reviewed, clinical knowledge and protocols were shared by multiple clinicians with direct expertise, and policy and public health context were added by expert authors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We describe xylazine\u2019s major harm domains\u2014acute poisoning, extended sedation, and wounds, along with anemia and hyperglycemia, which have been reported anecdotally but lack as clear of a connection to xylazine. Current successful practices for xylazine wound care are detailed. Understanding xylazine\u2019s epidemiology will also require greater investment in drug checking and surveillance. Finally, approaches to community-based wound care are discussed, along with an orientation to the larger policy and public health context.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Addressing the harms of xylazine requires interdisciplinary participation, investment in community-based harm reduction strategies, and improved drug supply surveillance. The relatively unique context of xylazine demands buy-in from public health professionals, harm reduction professionals, clinicians, basic science researchers, policymakers and more.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-023-00879-7","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:01:49Z","timestamp":1696078909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Reducing the harms of xylazine: clinical approaches, research deficits, and public health context"],"prefix":"10.1186","volume":"20","author":[{"given":"Claire M.","family":"Zagorski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Hosey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Moraff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Figgatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Aronowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"McElligott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabarun","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"issue":"4","key":"879_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","volume":"11","author":"SA Greene","year":"1988","unstructured":"Greene SA, Thurmon JC. Xylazine\u2014a review of its pharmacology and use in veterinary medicine. J Vet Pharmacol Ther. 1988;11(4):295\u2013313. https:\/\/doi.org\/10.1111\/j.1365-2885.1988.tb00189.x.","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"879_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/jvp.12724","volume":"42","author":"T Kitano","year":"2019","unstructured":"Kitano T, Kobayashi T, Yamaguchi S, Otsuguro K. The alpha(2A) -adrenoceptor subtype plays a key role in the analgesic and sedative effects of xylazine. J Vet Pharmacol Ther. 2019;42(2):243\u20137. https:\/\/doi.org\/10.1111\/jvp.12724.","journal-title":"J Vet Pharmacol Ther"},{"key":"879_CR3","doi-asserted-by":"publisher","unstructured":"Bedard M, Murray J, et al. Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to naloxone administration. Preprint. Posted September 9, 2023. https:\/\/doi.org\/10.1101\/2023.09.08.556914","DOI":"10.1101\/2023.09.08.556914"},{"key":"879_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","volume":"240","author":"K Ruiz-Colon","year":"2014","unstructured":"Ruiz-Colon K, Chavez-Arias C, Diaz-Alcala JE, Martinez MA. Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int. 2014;240:1\u20138. https:\/\/doi.org\/10.1016\/j.forsciint.2014.03.015.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"879_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","volume":"89","author":"JC Reyes","year":"2012","unstructured":"Reyes JC, Negron JL, Colon HM, et al. The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health. 2012;89(3):519\u201326. https:\/\/doi.org\/10.1007\/s11524-011-9662-6.","journal-title":"J Urban Health"},{"key":"879_CR6","doi-asserted-by":"publisher","unstructured":"Rodriguez N, Vargas Vidot J, Panelli J, Colon H, Ritchie B, Yamamura Y. GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles. Drug Alcohol Depend.2008;96(3):290\u20133. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.03.005","DOI":"10.1016\/j.drugalcdep.2008.03.005"},{"issue":"8","key":"879_CR7","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136. https:\/\/doi.org\/10.2105\/AJPH.2022.306881.","journal-title":"Am J Public Health"},{"key":"879_CR8","unstructured":"Moraff C. \"\u201cTranq Dope\u201d\u2014The Heroin Combo That\u2019s Been Putting Philly to Sleep.\" Filter Magazine. 2 April 2019. Online. https:\/\/filtermag.org\/tranq-dope-the-heroin-combo-thats-been-putting-philly-to-sleep\/"},{"key":"879_CR9","unstructured":"Krishnan M. A Horrifying Drug Called \u2018Tranq Dope\u2019 Is Spreading in the US. Vice News. Nov 15, 2022. https:\/\/www.vice.com\/en\/article\/akeqje\/tranq-dope-in-united-states"},{"key":"879_CR10","doi-asserted-by":"publisher","unstructured":"Montero F, Bourgois P, Friedman J. Potency-enhancing synthetics in the drug overdose epidemic: Xylazine (\u201cTranq\u201d), fentanyl, methamphetamine, and the displacement of heroin in Philadelphia and Tijuana. J Illicit Econ Dev. 2022;4(2):204\u2013222. https:\/\/doi.org\/10.31389\/jied.122","DOI":"10.31389\/jied.122"},{"key":"879_CR11","doi-asserted-by":"publisher","unstructured":"Lambdin BH, Bluthenthal RN, Zibbell JE, Wenger L, Simpson K, Kral AH. Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs. Int J Drug Policy. 2019;74:299\u2013304. https:\/\/doi.org\/10.1016\/j.drugpo.2019.10.004.","DOI":"10.1016\/j.drugpo.2019.10.004"},{"issue":"2\u20133","key":"879_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.10.014","volume":"88","author":"J Ahern","year":"2007","unstructured":"Ahern J, Stuber J, Galea S. Stigma, discrimination and the health of illicit drug users. Drug Alcohol Depend. 2007;88(2\u20133):188\u201396. https:\/\/doi.org\/10.1016\/j.drugalcdep.2006.10.014.","journal-title":"Drug Alcohol Depend"},{"key":"879_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12954-021-00528-x","volume":"18","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar ZR, Vincent L, et al. Treatment experiences for skin and soft tissue infections among participants of syringe service programs in North Carolina. Harm Reduct J. 2021;18:80. https:\/\/doi.org\/10.1186\/s12954-021-00528-x.","journal-title":"Harm Reduct J"},{"issue":"8","key":"879_CR14","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","volume":"60","author":"NS Ball","year":"2022","unstructured":"Ball NS, Knable BM, Relich TA, Smathers AN, Gionfriddo MR, Nemecek BD, Montepara CA, Guarascio AJ, Covvey JR, Zimmerman DE. Xylazine poisoning: a systematic review. Clin Toxicol. 2022;60(8):892\u2013901. https:\/\/doi.org\/10.1080\/15563650.2022.2063135.","journal-title":"Clin Toxicol"},{"key":"879_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, Shover C. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233: 109380. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109380.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"879_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bcp.12731","volume":"81","author":"ML Sivilotti","year":"2016","unstructured":"Sivilotti ML. Flumazenil, naloxone and the \u201ccoma cocktail.\u201d Br J Clin Pharmacol. 2016;81(3):428\u201336. https:\/\/doi.org\/10.1111\/bcp.12731.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"879_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2344\/0003-3006-62.1.31","volume":"62","author":"JA Giovannitti","year":"2015","unstructured":"Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: A review of current clinical applications. Anesth Prog. 2015;62(1):31\u20138. https:\/\/doi.org\/10.2344\/0003-3006-62.1.31.","journal-title":"Anesth Prog"},{"key":"879_CR18","doi-asserted-by":"publisher","unstructured":"Ehrman-Dupre R, Kaigh C, Salzman M, Haroz R, Peterson LK, Schmidt R. Management of Xylazine withdrawal in a hospitalized patient: a case report. J Addict Med. 2022;16(5):595\u2013598. https:\/\/doi.org\/10.1097\/ADM.0000000000000955","DOI":"10.1097\/ADM.0000000000000955"},{"key":"879_CR19","unstructured":"Lyder CH, Ayello EA. Pressure ulcers: a patient safety issue. In: Hughes RG, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Apr. Chapter 12. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK2650\/"},{"key":"879_CR20","doi-asserted-by":"publisher","unstructured":"Mitchell A. Adult pressure area care: Preventing pressure ulcers. Br J Nurs 2018;27(18), 1050\u20131052. https:\/\/doi.org\/10.12968\/bjon.2018.27.18.1050","DOI":"10.12968\/bjon.2018.27.18.1050"},{"issue":"11","key":"879_CR21","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1007\/s00421-021-04764-8","volume":"121","author":"P Ramondou","year":"2021","unstructured":"Ramondou P, Hersant J, Bernardeau E, Moumneh T, Feuilloy M, Henni S, Abraham P. Kneeling-induced calf ischemia: a pilot study in apparently healthy European young subjects. Eur J Appl Physiol. 2021;121(11):3031\u201340. https:\/\/doi.org\/10.1007\/s00421-021-04764-8.","journal-title":"Eur J Appl Physiol"},{"key":"879_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.tcr.2017.09.002","volume":"11","author":"D Clarke","year":"2017","unstructured":"Clarke D, Mullings S, Franklin S, Jones K. Well leg compartment syndrome. Trauma Case Rep. 2017;11:5\u20137. https:\/\/doi.org\/10.1016\/j.tcr.2017.09.002.","journal-title":"Trauma Case Rep"},{"issue":"1","key":"879_CR23","first-page":"43","volume":"25","author":"A Abbey","year":"2001","unstructured":"Abbey A, Zawacki T, Buck PO, Clinton AM, McAuslan P. Alcohol and sexual assault. Alcohol Res Health. 2001;25(1):43\u201351.","journal-title":"Alcohol Res Health"},{"issue":"1","key":"879_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.idc.2020.10.006","volume":"35","author":"HF Chambers","year":"2021","unstructured":"Chambers HF. Skin and soft tissue infections in persons who inject drugs. Infect Dis Clin N Am. 2021;35(1):169\u201381. https:\/\/doi.org\/10.1016\/j.idc.2020.10.006.","journal-title":"Infect Dis Clin N Am"},{"key":"879_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","volume":"198","author":"DL Biancarelli","year":"2019","unstructured":"Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, Bazzi AR. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"879_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaad.2015.08.070","volume":"74","author":"J Powers","year":"2016","unstructured":"Powers J, Higham C, Broussard K, Phillips TJ. Wound healing and treating wounds. J Am Acad Dermatol. 2016;74(4):607\u201325. https:\/\/doi.org\/10.1016\/j.jaad.2015.08.070.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"879_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/01.ASW.0000428861.26671.41","volume":"26","author":"RG Wilkins","year":"2013","unstructured":"Wilkins RG, Unverdorben M. Wound cleaning and wound healing: a concise review. Adv Skin Wound Care. 2013;26(4):160\u20133. https:\/\/doi.org\/10.1097\/01.ASW.0000428861.26671.41.","journal-title":"Adv Skin Wound Care"},{"issue":"3","key":"879_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00129334-200604000-00011","volume":"19","author":"G Brown","year":"2006","unstructured":"Brown G. Wound documentation: managing risk. Adv Skin Wound Care. 2006;19(3):155\u201365.","journal-title":"Adv Skin Wound Care"},{"issue":"2","key":"879_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/wrr.12117","volume":"22","author":"J Majtan","year":"2014","unstructured":"Majtan J. Honey: an immunomodulator in wound healing. Wound Repair Regen. 2014;22(2):187\u201392.","journal-title":"Wound Repair Regen"},{"key":"879_CR30","unstructured":"Bryant RA, Nix DP. Chapter 17: wound debridement. In Acute & chronic wounds: current management concepts (pp. 295\u2013305). 2017. Elsevier."},{"issue":"3","key":"879_CR31","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin infect Dis. 2011;52(3):e18\u201355.","journal-title":"Clin infect Dis."},{"key":"879_CR32","unstructured":"Smith+Nephew. How to apply Collagenase SANTYL\u25ca Ointment. Accessed 12 April 2023. https:\/\/santyl.com\/how-to-apply"},{"issue":"899","key":"879_CR33","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/pmj.76.899.561","volume":"76","author":"AR Mackenzie","year":"2000","unstructured":"Mackenzie AR, Laing RB, Douglas JG, Greaves M, Smith CC. High prevalence of iliofemoral venous thrombosis with severe groin infection among injecting drug users in North East Scotland: successful use of low molecular weight heparin with antibiotics. Postgrad Med J. 2000;76(899):561\u20135. https:\/\/doi.org\/10.1136\/pmj.76.899.561.","journal-title":"Postgrad Med J"},{"issue":"4","key":"879_CR34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1080\/09595230802089701","volume":"27","author":"Z Hoda","year":"2008","unstructured":"Hoda Z, Kerr T, Li K, Montaner JS, Wood E. Prevalence and correlates of jugular injections among injection drug users. Drug Alcohol Rev. 2008;27(4):442\u20136. https:\/\/doi.org\/10.1080\/09595230802089701.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"879_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.11606\/issn.2318-3659.v49i2p139-145","volume":"49","author":"AM Ambrosio","year":"2012","unstructured":"Ambrosio AM, Keila Kazue IDA, Souto MTDMR, Claudio L, da Silva LC, Soares PB, Marcelo T. Significant hematocrit decrease in healthy horses during clinical anesthesia. Braz J Vet Res Anim Sci. 2012;49(2):139\u201345.","journal-title":"Braz J Vet Res Anim Sci"},{"issue":"1","key":"879_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2253-13-33","volume":"13","author":"YF Xiao","year":"2013","unstructured":"Xiao YF, Wang B, Wang X, Du F, Benzinou M, Wang YX. Xylazine-induced reduction of tissue sensitivity to insulin leads to acute hyperglycemia in diabetic and normoglycemic monkeys. BMC Anesthesiol. 2013;13(1):33. https:\/\/doi.org\/10.1186\/1471-2253-13-33.","journal-title":"BMC Anesthesiol"},{"issue":"10","key":"879_CR37","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1089\/wound.2020.1243","volume":"10","author":"DP Sanchez","year":"2021","unstructured":"Sanchez DP, Tookes H, Pastar I, Lev-Tov H. Wounds and skin and soft tissue infections in people who inject drugs and the utility of syringe service programs in their management. Adv Wound Care (New Rochelle). 2021;10(10):571\u201382. https:\/\/doi.org\/10.1089\/wound.2020.1243.","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"1","key":"879_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12954-020-00372-5","volume":"17","author":"G Kolla","year":"2020","unstructured":"Kolla G, Strike C. Practices of care among people who buy, use, and sell drugs in community settings. Harm Reduct J. 2020;17(1):27. https:\/\/doi.org\/10.1186\/s12954-020-00372-5.","journal-title":"Harm Reduct J"},{"issue":"2","key":"879_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/aje\/kwab233","volume":"191","author":"N Dasgupta","year":"2022","unstructured":"Dasgupta N, Figgatt MC. Invited commentary: drug checking for novel insights into the unregulated drug supply. Am J Epidemiol. 2022;191(2):248\u201352. https:\/\/doi.org\/10.1093\/aje\/kwab233.","journal-title":"Am J Epidemiol"},{"key":"879_CR40","unstructured":"03\u2014Standards and schedules. The Florida Senate. Accessed 12 April 2023. https:\/\/www.flsenate.gov\/laws\/statutes\/2018\/893.03"},{"key":"879_CR41","unstructured":"Drug Enforcement Administration. The Growing Threat of Xylazine and its Mixture with Illicit Drugs. DEA Joint Intelligence Report. October 2022. https:\/\/www.dea.gov\/sites\/default\/files\/2022-12\/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf"},{"key":"879_CR42","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2017.05.050","volume":"46","author":"L Beletsky","year":"2017","unstructured":"Beletsky L, Davis CS. Today\u2019s fentanyl crisis: prohibition\u2019s iron law, revisited. Int J Drug Policy. 2017;46:156\u20139. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.050.","journal-title":"Int J Drug Policy"}],"updated-by":[{"DOI":"10.1186\/s12954-023-00903-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000}}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00879-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T09:08:15Z","timestamp":1710752895000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00879-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00879-7","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12954-023-00903-w","URL":"https:\/\/doi.org\/10.1186\/s12954-023-00903-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable: this article does not include human or animal research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}